Cervical adenocarcinoma is an acquired malignancy that develops over time from glandular cells of the cervix. It is not a hereditary condition and does not run in families in a Mendelian pattern. Persistent infection with high-risk human papillomavirus (HPV) is a recognized contributing factor in many cases, though the role of HPV in adenocarcinoma differs from squamous cell cervical cancer. The genetic basis underlying tumor development is an active area of research.

Diagnosis typically begins with cervical cancer screening, which may include cytology (Pap testing) and HPV testing. Suspicious findings prompt colposcopy and cervical biopsy for histologic confirmation. Microscopic evaluation distinguishes adenocarcinoma from squamous cell carcinoma and identifies subtypes such as endocervical mucinous, clear cell, endometrioid, serous, and adenosquamous variants. Differential diagnosis includes squamous cell cervical carcinoma, adenosquamous carcinoma, and endometrial adenocarcinoma involving the cervix. Imaging may be used for staging.

Treatment planning for cervical adenocarcinoma depends on disease stage, tumor characteristics, and overall health. Management often involves a multidisciplinary oncology team and may include surgery, local therapies such as radiation, systemic treatment approaches, and supportive care. Treatment goals are individualized and may focus on disease control, symptom management, or curative intent depending on the specific situation. Patients should consult their healthcare team to discuss options appropriate for their situation.

Outcomes depend on stage at diagnosis, tumor characteristics, and response to treatment. Survival outcomes have improved with advances in screening and treatment. Early detection through cervical cancer screening and access to specialized oncology care can improve outcomes. Individual response to treatment varies, and prognosis is best discussed with the treating oncology team.

Cervical adenocarcinoma is an active research area with numerous ongoing clinical trials. Current studies are investigating immunotherapy approaches, HPV-targeted T-cell therapies for HPV-associated cancers, and novel chemoradiation strategies. Individuals interested in clinical trials can search ClinicalTrials.gov or consult their care team.